In a well‐written and informative article, Whittle et al[^1^](#emp212131-bib-0001){ref-type="ref"} "Respiratory Support for Adult Patients with COVID‐19," correctly recommend against using nebulizer therapy for asthmatics and suggests metered‐dose inhalers.

During the COVID‐19 epidemic, asthmatics will continue to have exacerbations, frequently requiring emergency room care in a physician\'s office, urgent care center, or emergency department of a hospital. It is recommended that asthmatic patients continue to be managed according to asthma guideline recommendations.[^2^](#emp212131-bib-0002){ref-type="ref"} Nebulizer use is discouraged unless essential during a pandemic because nebulized therapy is more likely to aerosolize SARS‐CoV‐2 and increase risk of contagion. As such, asthma therapy delivered by a metered‐dose inhaler would be more appropriate in the healthcare setting.[^3^](#emp212131-bib-0003){ref-type="ref"}

Nevertheless, some patients are so tight that using a metered‐dose inhaler, even with a spacer, might be problematic, particularly if they have uncontrolled coughing, have severe life‐threatening asthma, or those who are uncooperative or unable to follow directions required for the metered‐dose inhaler, even with a spacer.

A recent article[^4^](#emp212131-bib-0004){ref-type="ref"} demonstrated that, in a prospective study, 85 asthmatic patients treated with subcutaneous terbutaline significantly improved after already receiving multiple albuterol treatments with either nebulized aerosols or albuterol metered‐dose inhalers. Advantages of terbutaline over epinephrine include: (1) a more pronounced effect with a longer duration of action on forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC),[^5^](#emp212131-bib-0005){ref-type="ref"} and (2) preferred over epinephrine in pregnancy.[^6^](#emp212131-bib-0006){ref-type="ref"} Terbutaline is inexpensive and readily accessible, even though a previous survey of physicians in the Cleveland area reveal that 98% of physicians rarely or never use subcutaneous terbutaline for an exacerbation of asthma.[^7^](#emp212131-bib-0007){ref-type="ref"} From a colleague in New York City reading about my work with terbutaline, "This is great! Not only that, but the feasibility of subcutaneous terbutaline as an administration route during a high‐volume/war‐like situation is underappreciated."

Additionally, the American College of Allergy, Asthma, and Immunology (ACAAI) has reported that some areas around the country are experiencing shortages in albuterol inhalers as a result of an increased demand, because hospitals are using inhalers rather than nebulizers to treat COVID‐19 patients.[^8^](#emp212131-bib-0008){ref-type="ref"}

Finally, although metered‐dose inhalers frequently work, the use of subcutaneous terbutaline would obviate the need for these inhalers or aerosols.
